The conversation about GLP-1 receptor agonists has been dominated by the number on the bathroom scale.
Weight loss is real, visible and easy to communicate, and it has carried these medicines into the public imagination faster than almost any drug class in living memory.
But it is a reductive way to think about what they do. Framing semaglutide and its peers as weight loss drugs sells short their most important promise – the treatment of metabolic dysfunction.
Check out the rest of the feature here
